Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 325-330

  Giordano, Paola ^a   Molinari, Angelo Claudio ^b   Del Vecchio, Giovanni Carlo ^a   Saracco, Paola ^c   Russo, Giovanna ^d   Altomare, Maria ^a   Perutelli, Paolo ^b   Crescenzio, Nicoletta ^c   Santoro, Nicola ^a   Marchetti, Marina ^e   De Mattia, Domenico ^a   Falanga, Anna ^e  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; CYCLOPHOSPHAMIDE; CYTARABINE; D DIMER; DAUNORUBICIN; FIBRINOGEN; INTERLEUKIN 6; METHOTREXATE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; VON WILLEBRAND FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHILD; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VENOUS THROMBOEMBOLISM;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITHROMBINS; ASPARAGINASE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; METHOTREXATE; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROSPECTIVE STUDIES; RISK FACTORS; THROMBIN; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VINCRISTINE; VON WILLEBRAND FACTOR;

EID: 77951575045     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21665     Document Type: Article

References (39)

1. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
2. Falanga A, Marchetti M. Venous thromboembolism in the hematological malignancies. J Clin Oncol 2009;27:4848-4857.
3. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival. Blood 2009;113:3911-3917.
4. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, De Gaetano G, Donati MB. Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216-2222. (Pubitemid 44497502)
5. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007;138:430-445.
6. Giordano P, Santoro N, Del Vecchio GC. T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study. Haematologica 2003;88:1079-1080. (Pubitemid 37151165)
7. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110.
8. Alessio MG, Falanga A, Consonni R. Cancer procoagulant in acute lymphoblastic leukemia. Eur J Haematol 1990;45:78-81. (Pubitemid 20310107)
9. Uszyński M, Osińska M, Zekanowska E, Ziół kowska E. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes. Med Sci Monit 2000; 2000; ;6:108-111. (Pubitemid 30158250)
10. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111:199-212.
11. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003;111:125-131.
12. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood 1994;83:386-391. (Pubitemid 24978033)
13. Giordano P, Del Vecchio GC, Santoro N. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. Pediatr Hematol Oncol 2000;17:667-672.
14. Rizzari C, Citterio M, Zucchetti M. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24-31. (Pubitemid 43235382)
15. Perutelli P, Amato S, Minniti G. von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women. Blood Coagul Fibrinolysis 2005;16:267-273. (Pubitemid 40705048)
16. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829. (Pubitemid 41798294)
17. Ay C, Vormittag R, Dunkler D. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124-4129.
18. Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 112: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemostasis 1991;65:28-31.
19. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: Implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003;1:673-678.
20. Falanga A, Iacoviello L, Evangelista V. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995;86:1072-1081.
21. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-430.
22. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004;114:321-327.
23. Van Aken BE, Den Heijer M, Bos GM, Van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemostasis 2000;83:536-539. (Pubitemid 30201126)
24. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005;3:1710-1716. (Pubitemid 41716557)
25. Donadelli R, Orje JN, Capoferri C. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood 2006;107:1943-1950. (Pubitemid 43289375)
26. Bernardo A, Ball C, Nolasco L, Moake JF, Dong J-f. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004;104:100-106. (Pubitemid 38879844)
27. Yamamoto Y, Ishizu A, Ikeda H. Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha. Pathobiology: J Immunopathol Mol Cell Biol 2004;71:295-301. (Pubitemid 40082308)
28. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006;54;54:75-84. (Pubitemid 44257345)
29. Merten M, Thiagarajan P. P-selectin in arterial thrombosis. Z Für Kardiologie 2004;93:855-863.
30. Ay C, Simanek R, Vormittag R. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-2708.
31. Nowak-Gottl U, Ahlke E, Fleischhack G. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529-2533. (Pubitemid 36857608)
32. Jilma B, Cvitko T, Winter-Fabry A. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost 2005;94:797-801. (Pubitemid 41489240)
33. Mitchell CD, Richards SM, Kinsey SE. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745.
34. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 1995;21:390-401. (Pubitemid 26010008)
35. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. An Int J Haemost Thromb 1994;5:(Suppl 1)S24-S36. (Pubitemid 24049883)
36. Hunault-Berger M, Chevallier P, Delain M. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: The CAPELAL study. Haematologica 2008;93:1488-1494.
37. Leone G, Gugliotta L, Mazzucconi MG. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost 1993;69:12-15. (Pubitemid 23026189)
38. Appel IM, Hop WC, Van Kessel-Bakvis C. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008;100:330-337.
39. Nowak-Göttl U, Heinecke A, Von Kries R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-172. (Pubitemid 32728101)